{"id":"W2085518532","doi":"10.1016/j.ejca.2011.05.017","title":"Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Pazopanib; Placebo; Medicine; Renal cell carcinoma; Quality of life (healthcare); Oncology; Internal medicine; Clinical trial; Phases of clinical research; Alternative medicine; Sunitinib; Pathology; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001387387,0.001626097,0.004110382,0.0003148531,0.0004412569,0.001157051,0.0007981362,0.001516008,0.005118171],"category_scores_gemma":[0.001675854,0.0006832842,0.002778443,0.0004917874,0.001361487,0.0011611,0.0004767849,0.004015788,0.000650037],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000810487,"about_ca_system_score_gemma":0.0008542898,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007557448,"about_ca_topic_score_gemma":0.001375097,"domain_scores_codex":[0.9993267,0.0003658753,0.00004064921,0.0001232298,0.00003973325,0.0001038495],"domain_scores_gemma":[0.9992305,0.0002628728,0.0001659423,0.00006191512,0.00003778365,0.000240978],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9873964,0.00233088,0.0005380489,0.0003558211,0.0007686748,0.00002908878,0.00003038326,0.0002529755,0.001300693,0.00005085696,0.0002947005,0.006651578],"study_design_scores_gemma":[0.954637,0.04257103,0.001648562,0.00001525419,0.0004354646,0.00002113149,0.00001341123,0.0001988716,0.0001462252,0.00008325125,0.0002221514,0.000007666213],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9911595,0.004241463,0.0004041857,0.0007514596,0.0004816699,0.001238069,0.0006291795,0.00006058356,0.001033903],"genre_scores_gemma":[0.9928125,0.002173127,0.0005813544,0.000629538,0.0003492547,0.001666784,0.0007104697,0.00001247646,0.001064557],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005118171,"threshold_uncertainty_score":0.01712197,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05298764010998183,"score_gpt":0.3047085310886384,"score_spread":0.2517208909786566,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}